Treatment of lung disorders

• US 20040192595A1
• Filed: 03/25/2003
• Published: 09/30/2004
• Est. Priority Date: 04/01/2002
• Status: Abandoned Application

• Current Assignee: Daniel L. Traber, David N. Herndon, Donald S. Prough, Kazunori Murakami, Lillian D. Traber, Perenlei Enkhbaatar
• Original Assignee: Daniel L. Traber, David N. Herndon, Donald S. Prough, Kazunori Murakami, Lillian D. Traber, Perenlei Enkhbaatar
• Inventors: Herndon, David N., Murakami, Kazunori, Traber, Daniel L., Enkhbaatar, Perenlei, Prough, Donald S., Traber, Lillian D.
• Application Number:
  US10/396,855
• Publication Number:
  US 20040192595A1
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 38/57 from animals; from humans A61K38/553, A61K38/556 take precedence
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system

Abstract

The invention features methods of treating a subject having a lung disorder such as lung inflammation and injury, by administering antithrombin III by inhalation.

Claims

1. A method of treating acute lung injury in a subject, comprising:

administering by inhalation a therapeutically effective amount of antithrombin III such that the lung injury is treated;

wherein the antithrombin III is administered at a dose of about 10-300 U/kg of body weight; and

,

wherein the antithrombin III is administered in the lungs at the site of the proximate acute injury.

2. The method of claim 1, wherein the lung injury is septic acute lung injury.

3. The method of claim 1, wherein the lung injury is acute respiratory distress syndrome (ARDS).

4. The method of claim 1, wherein the lung injury is in response to exposure to a viral agent.

5. The method of claim 4, wherein said viral agent is Pseudomonas pneumonia.

6. The method of claim 1, wherein the lung injury is in response to smoke or smoke and asbestos.

7. The method of claim 1, wherein the antithrombin III is administered using an ultrasonic nebulizer.

8. The method of claim 1, wherein the antithrombin III is plasma derived antithrombin III.

9. The method of claim 1, wherein the antithrombin III is recombinantly produced antithrombin III.

10. The method of claim 9, wherein the recombinantly produced antithrombin III is transgenically produced antithrombin III.

11. The method of claim 1, wherein the subject is administered more than one dose of the antithrombin III.

13. The method of claim 1, wherein the antithrombin III is administered at a dose of about 25-125 U/kg of body weight.

14. A method of treating acute lung injury in a subject, comprising:

administering by inhalation a therapeutically effective amount of antithrombin III such that the lung injury is treated; and

,

wherein said lung injury is in response to the activity of Pseudomonas aeruginosa; and

,

wherein the antithrombin III administered is transgenically produced antithrombin III; and

wherein the antithrombin III is administered at a dose of about 10-300 U/kg of body weight.